The global LFA-based Cardiac market size is predicted to grow from US$ 4381 million in 2025 to US$ 6148 million in 2031; it is expected to grow at a CAGR of 5.8% from 2025 to 2031.
Lateral flow cardiac markers are a rapid detection tool based on lateral flow immunochromatography technology, which is used to qualitatively or quantitatively detect specific cardiac biomarkers in the blood (such as troponin I/T, myoglobin, BNP, etc.). The principle is to form a visual detection line on the test strip through antigen-antibody reaction, so as to quickly judge abnormal cardiac function or myocardial damage. This technology has the advantages of convenience, rapidity (results in 15-30 minutes), low cost, and no need for complex equipment. It is widely used in emergency, primary care, home self-testing and other scenarios.
Market drivers:
Disease demand growth:
Cardiovascular disease is the world's leading cause of death, with a large and growing patient base. China has more than 330 million cardiovascular disease patients, and there is an urgent need for early screening and immediate diagnosis.
Acute myocardial infarction, heart failure and other acute diseases require rapid testing (such as the demand for troponin immediate testing in chest pain centers), and lateral flow technology can shorten the diagnosis time and improve prognosis.
Policy promotion:
Tiered diagnosis and treatment: Policies guide the sinking of high-quality medical resources, and primary medical institutions (such as community hospitals and township health centers) need to be equipped with POCT (point-of-care testing) equipment. Lateral flow cardiac markers are the first choice because of their simple operation and low cost.
Medical insurance coverage: Some cardiac marker tests are included in medical insurance, reducing the burden on patients and improving the accessibility of testing.
Technology iteration:
Sensitivity improvement: The application of nanomaterials (such as gold nanoparticles) improves detection sensitivity and can detect low-concentration markers (such as high-sensitivity troponin).
Multi-indicator joint detection: The same test strip realizes the joint detection of multiple markers (such as troponin + BNP + D-dimer), improving diagnostic efficiency.
Intelligence: Combined with mobile phone APP or portable reader, the results can be automatically transmitted and interpreted to reduce human errors.
Application scenario expansion:
Pre-hospital emergency: rapid screening at ambulance and emergency scene, auxiliary decision-making (such as whether to transfer directly to the catheterization room).
Home monitoring: patients with chronic heart failure can self-test BNP at home and adjust drug dosage in time.
Physical examination screening: early cardiac function assessment for high-risk groups (such as patients with hypertension and diabetes).
Market trend:
Domestic substitution: domestic companies (such as Wondfo Biotech and Mindray Biotech) have made technological breakthroughs, breaking the import monopoly and reducing costs.
Standardized development: industry standards are gradually improved, promoting the transformation of product homogeneity to differentiated competition (such as specific marker detection and personalized services).
The lateral flow cardiac marker market is driven by disease demand, policy promotion, and technological upgrading. In the future, it will continue to develop in the direction of rapidity, multi-indicators, and intelligence, and become an important tool for the diagnosis and treatment of cardiovascular diseases.
The 鈥淟FA-based Cardiac Industry Forecast鈥� looks at past sales and reviews total world LFA-based Cardiac sales in 2024, providing a comprehensive analysis by region and market sector of projected LFA-based Cardiac sales for 2025 through 2031. With LFA-based Cardiac sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world LFA-based Cardiac industry.
This Insight Report provides a comprehensive analysis of the global LFA-based Cardiac landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on LFA-based Cardiac portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global LFA-based Cardiac market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for LFA-based Cardiac and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global LFA-based Cardiac.
This report presents a comprehensive overview, market shares, and growth opportunities of LFA-based Cardiac market by product type, application, key players and key regions and countries.
Segmentation by Type:
Troponin I
Troponin T
CK-MB
Myoglobin
Others
Segmentation by Application:
Laboratory Testing
Point-of-care Testing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche
Abbott
Siemens
Danaher
Bio-Rad Laboratories
叠颈辞惭茅谤颈别耻虫
Thermo Fisher
Ortho Clinical Diagnostics
LSI Medience Corporation
Randox laboratories
Wondfo Biotech
EasyDiagnosis Biomedicine
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global LFA-based Cardiac Market Size (2020-2031)
2.1.2 LFA-based Cardiac Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for LFA-based Cardiac by Country/Region (2020, 2024 & 2031)
2.2 LFA-based Cardiac Segment by Type
2.2.1 Troponin I
2.2.2 Troponin T
2.2.3 CK-MB
2.2.4 Myoglobin
2.2.5 Others
2.3 LFA-based Cardiac Market Size by Type
2.3.1 LFA-based Cardiac Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global LFA-based Cardiac Market Size Market Share by Type (2020-2025)
2.4 LFA-based Cardiac Segment by Application
2.4.1 Laboratory Testing
2.4.2 Point-of-care Testing
2.5 LFA-based Cardiac Market Size by Application
2.5.1 LFA-based Cardiac Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global LFA-based Cardiac Market Size Market Share by Application (2020-2025)
3 LFA-based Cardiac Market Size by Player
3.1 LFA-based Cardiac Market Size Market Share by Player
3.1.1 Global LFA-based Cardiac Revenue by Player (2020-2025)
3.1.2 Global LFA-based Cardiac Revenue Market Share by Player (2020-2025)
3.2 Global LFA-based Cardiac Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 LFA-based Cardiac by Region
4.1 LFA-based Cardiac Market Size by Region (2020-2025)
4.2 Global LFA-based Cardiac Annual Revenue by Country/Region (2020-2025)
4.3 Americas LFA-based Cardiac Market Size Growth (2020-2025)
4.4 APAC LFA-based Cardiac Market Size Growth (2020-2025)
4.5 Europe LFA-based Cardiac Market Size Growth (2020-2025)
4.6 Middle East & Africa LFA-based Cardiac Market Size Growth (2020-2025)
5 Americas
5.1 Americas LFA-based Cardiac Market Size by Country (2020-2025)
5.2 Americas LFA-based Cardiac Market Size by Type (2020-2025)
5.3 Americas LFA-based Cardiac Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC LFA-based Cardiac Market Size by Region (2020-2025)
6.2 APAC LFA-based Cardiac Market Size by Type (2020-2025)
6.3 APAC LFA-based Cardiac Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe LFA-based Cardiac Market Size by Country (2020-2025)
7.2 Europe LFA-based Cardiac Market Size by Type (2020-2025)
7.3 Europe LFA-based Cardiac Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa LFA-based Cardiac by Region (2020-2025)
8.2 Middle East & Africa LFA-based Cardiac Market Size by Type (2020-2025)
8.3 Middle East & Africa LFA-based Cardiac Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global LFA-based Cardiac Market Forecast
10.1 Global LFA-based Cardiac Forecast by Region (2026-2031)
10.1.1 Global LFA-based Cardiac Forecast by Region (2026-2031)
10.1.2 Americas LFA-based Cardiac Forecast
10.1.3 APAC LFA-based Cardiac Forecast
10.1.4 Europe LFA-based Cardiac Forecast
10.1.5 Middle East & Africa LFA-based Cardiac Forecast
10.2 Americas LFA-based Cardiac Forecast by Country (2026-2031)
10.2.1 United States Market LFA-based Cardiac Forecast
10.2.2 Canada Market LFA-based Cardiac Forecast
10.2.3 Mexico Market LFA-based Cardiac Forecast
10.2.4 Brazil Market LFA-based Cardiac Forecast
10.3 APAC LFA-based Cardiac Forecast by Region (2026-2031)
10.3.1 China LFA-based Cardiac Market Forecast
10.3.2 Japan Market LFA-based Cardiac Forecast
10.3.3 Korea Market LFA-based Cardiac Forecast
10.3.4 Southeast Asia Market LFA-based Cardiac Forecast
10.3.5 India Market LFA-based Cardiac Forecast
10.3.6 Australia Market LFA-based Cardiac Forecast
10.4 Europe LFA-based Cardiac Forecast by Country (2026-2031)
10.4.1 Germany Market LFA-based Cardiac Forecast
10.4.2 France Market LFA-based Cardiac Forecast
10.4.3 UK Market LFA-based Cardiac Forecast
10.4.4 Italy Market LFA-based Cardiac Forecast
10.4.5 Russia Market LFA-based Cardiac Forecast
10.5 Middle East & Africa LFA-based Cardiac Forecast by Region (2026-2031)
10.5.1 Egypt Market LFA-based Cardiac Forecast
10.5.2 South Africa Market LFA-based Cardiac Forecast
10.5.3 Israel Market LFA-based Cardiac Forecast
10.5.4 Turkey Market LFA-based Cardiac Forecast
10.6 Global LFA-based Cardiac Forecast by Type (2026-2031)
10.7 Global LFA-based Cardiac Forecast by Application (2026-2031)
10.7.1 GCC Countries Market LFA-based Cardiac Forecast
11 Key Players Analysis
11.1 Roche
11.1.1 Roche Company Information
11.1.2 Roche LFA-based Cardiac Product Offered
11.1.3 Roche LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Roche Main Business Overview
11.1.5 Roche Latest Developments
11.2 Abbott
11.2.1 Abbott Company Information
11.2.2 Abbott LFA-based Cardiac Product Offered
11.2.3 Abbott LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Abbott Main Business Overview
11.2.5 Abbott Latest Developments
11.3 Siemens
11.3.1 Siemens Company Information
11.3.2 Siemens LFA-based Cardiac Product Offered
11.3.3 Siemens LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Siemens Main Business Overview
11.3.5 Siemens Latest Developments
11.4 Danaher
11.4.1 Danaher Company Information
11.4.2 Danaher LFA-based Cardiac Product Offered
11.4.3 Danaher LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Danaher Main Business Overview
11.4.5 Danaher Latest Developments
11.5 Bio-Rad Laboratories
11.5.1 Bio-Rad Laboratories Company Information
11.5.2 Bio-Rad Laboratories LFA-based Cardiac Product Offered
11.5.3 Bio-Rad Laboratories LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Bio-Rad Laboratories Main Business Overview
11.5.5 Bio-Rad Laboratories Latest Developments
11.6 叠颈辞惭茅谤颈别耻虫
11.6.1 叠颈辞惭茅谤颈别耻虫 Company Information
11.6.2 叠颈辞惭茅谤颈别耻虫 LFA-based Cardiac Product Offered
11.6.3 叠颈辞惭茅谤颈别耻虫 LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 叠颈辞惭茅谤颈别耻虫 Main Business Overview
11.6.5 叠颈辞惭茅谤颈别耻虫 Latest Developments
11.7 Thermo Fisher
11.7.1 Thermo Fisher Company Information
11.7.2 Thermo Fisher LFA-based Cardiac Product Offered
11.7.3 Thermo Fisher LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Thermo Fisher Main Business Overview
11.7.5 Thermo Fisher Latest Developments
11.8 Ortho Clinical Diagnostics
11.8.1 Ortho Clinical Diagnostics Company Information
11.8.2 Ortho Clinical Diagnostics LFA-based Cardiac Product Offered
11.8.3 Ortho Clinical Diagnostics LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Ortho Clinical Diagnostics Main Business Overview
11.8.5 Ortho Clinical Diagnostics Latest Developments
11.9 LSI Medience Corporation
11.9.1 LSI Medience Corporation Company Information
11.9.2 LSI Medience Corporation LFA-based Cardiac Product Offered
11.9.3 LSI Medience Corporation LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 LSI Medience Corporation Main Business Overview
11.9.5 LSI Medience Corporation Latest Developments
11.10 Randox laboratories
11.10.1 Randox laboratories Company Information
11.10.2 Randox laboratories LFA-based Cardiac Product Offered
11.10.3 Randox laboratories LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Randox laboratories Main Business Overview
11.10.5 Randox laboratories Latest Developments
11.11 Wondfo Biotech
11.11.1 Wondfo Biotech Company Information
11.11.2 Wondfo Biotech LFA-based Cardiac Product Offered
11.11.3 Wondfo Biotech LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.11.4 Wondfo Biotech Main Business Overview
11.11.5 Wondfo Biotech Latest Developments
11.12 EasyDiagnosis Biomedicine
11.12.1 EasyDiagnosis Biomedicine Company Information
11.12.2 EasyDiagnosis Biomedicine LFA-based Cardiac Product Offered
11.12.3 EasyDiagnosis Biomedicine LFA-based Cardiac Revenue, Gross Margin and Market Share (2020-2025)
11.12.4 EasyDiagnosis Biomedicine Main Business Overview
11.12.5 EasyDiagnosis Biomedicine Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
